Erasca, Inc. ERAS
Erasca, Inc. (Nasdaq: ERAS) is an oncology drug developer. Its lead program, ERAS-0015, is in Phase 1 for RAS-mutant solid tumors (KRAS G12X NSCLC, pancreatic adenocarcinoma, colorectal cancer). Its next catalyst on record is ERAS-4001: Preliminary Phase 1 monotherapy safety, PK and initial efficacy data from BOREALIS-1 (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ERAS-4001 — Preliminary Phase 1 monotherapy safety, PK and initial efficacy data from BOREALIS-1 (H2 2026). 7 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ERAS-0015 (pan-RAS molecular glue; AURORAS-1) | RAS-mutant solid tumors (NSCLC, PDAC, CRC) | small molecule | Phase 1 |
| ERAS-4001 (pan-KRAS inhibitor; BOREALIS-1) | KRAS-mutated solid tumors | small molecule | Phase 1 |
| naporafenib (SEACRAFT-1/-2) | NRAS-mutant melanoma (license terminated effective 2026-06-03; existing patients continue treatment) | small molecule | Phase 1 |
| ERAS-12 (EGFR D2/D3 biparatopic antibody) | EGFR-driven tumors; seeking partner, no internal resources | antibody | Pre-clinical |
Recent results and decisions
- Aug 24, 2026n/a FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma.
On August 24, 2026, Erasca, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation (“FTD”) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma.
Filing - Aug 11, 2026positive Updated Phase 1 data (DCO May 25, 2026): ERAS-0015 monotherapy at 32 mg QD showed 57% uORR8wk in 2L+ KRAS G12X PDAC with no DLTs and no treatment-related discontinuations.
ERAS-0015 demonstrated encouraging monotherapy activity in second-line or later (2L+) KRAS G12X pancreatic ductal adenocarcinoma (PDAC), with a 57% uORR8wk and ongoing treatment across all responding patients and most enrolled patients.
Filing - Jul 13, 2026positive Updated Phase 1 AURORAS-1 data: 57% unconfirmed+confirmed ORR (n=7) at 32 mg QD in 2L+ KRAS G12X pancreatic cancer, generally well tolerated with no DLTs.
57% uORR8wk (N=7) at recommended dose for expansion (“RDE”) of 32 mg once daily (“QD”)
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.